

# Patient and Caregiver Views on Measures of the Value of Health Interventions

Dominic Voehler , Peter J Neumann, Daniel A Ollendorf 

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

Correspondence: Daniel A Ollendorf, Tufts Medical Center, 800 Washington St., #063, Boston, MA, 02111, USA, Tel +1 617 636 2581, Email [dollendorf@tuftsmedicalcenter.org](mailto:dollendorf@tuftsmedicalcenter.org)

**Purpose:** We aimed to investigate patient and caregiver views on the relative importance of traditional and nontraditional domains of value, and to determine if these views differed according to key demographic characteristics.

**Patients and Methods:** We conducted a modified Delphi approach using a web-based survey of adult patients managing a chronic condition or caregivers of a patient with chronic illness who were recruited using purposive sampling focused on demographic and clinical characteristics. The first survey round asked participants to rate the 13 domains of value on a 5-point Likert scale and rank each domain that they rated as important or very important. In the second survey round, participants reconsidered their own and aggregated round 1 results. New questions were added, including “rescuing” domains, challenges faced in taking medication, and a free-text option to add domains not already captured.

**Results:** Initial recruitment resulted in 79 participants. Sixty-three (79.7%) completed the first round, and 58 participants completed both rounds. Overall ratings and rankings were consistent between survey rounds, and respondents ranked most highly domains considered traditional domains of value (for example, survival, costs). Patient activists were about six times more likely to rate each domain as important or very important compared to general disease advocates. Significant factors associated with a higher odds of rating a domain as important or very important were age 35–54 and 55–64 compared to 18–34, while factors associated with a decreased odds were males and patients compared to caregivers.

**Conclusion:** Patients and caregivers place significant emphasis on traditional measures of value compared to nontraditional measures, and participants’ prior beliefs impact what aspects of value they deem important.

**Keywords:** cost-effectiveness analysis, value flower, patient preference, value assessment

## Introduction

The use of cost-effectiveness analysis (CEA) has increased worldwide as a key input into decisions around the adoption of and reimbursement for pharmaceuticals and other health technologies. The number of published CEAs increased globally from an average of 40 per year during the period 1990–2000 to an average of 740 per year from 2010 to 2020.<sup>1</sup> Despite being in the forefront of CEA methods and research, the United States has lagged behind other countries in the use of CEA for decision-making.<sup>2</sup> This situation has begun to change with the advent of organizations such as the nonprofit Institute for Clinical and Economic Review as well as increasing acceptance of CEA by payers and pharmacy benefit managers.<sup>3</sup>

With this acceptance has also come a revisiting of traditional methods in CEA, which typically express health gains in terms of quality-adjusted life years (QALYs) gained, and cost-effectiveness as a ratio of incremental costs incurred to incremental QALYs gained. While recognizing the usefulness of QALYs, many researchers and policy makers have also noted that QALYs have limitations when it comes to reflecting all important domains of health.<sup>4,5</sup> A common criticism is that QALYs are not patient focused.<sup>4</sup> Critics argue that patient preferences may not align with gains in health utilities; rather, patients are more concerned with tangible and direct impacts, like function, quality of life, and family impact.<sup>4</sup>

Others express concern that QALYs can be used to unfairly ration resources.<sup>5</sup> Some patient advocacy groups argue that value assessments utilizing the QALY seek to cap treatments and discriminate against people with disabilities.<sup>6,7</sup>

Researchers have begun addressing these concerns through exploration of nontraditional measures of the value to incorporate into a more comprehensive CEA, whether as an adjustment to QALY estimation or to support alternative measures of health gain.<sup>8</sup> Examples include measures of equity (ie, addressing disadvantaged populations), the value of “hope” (capturing individual’s willingness to pay for a small chance of large health gains), and “real option” value (the value inherent in a small incremental gain from a treatment that allows survival long enough to achieve gains from further medical advances).<sup>8</sup>

While research on these domains include patient and caregiver preferences to date, there have not been efforts to assess the views of these groups on the merits of these attributes. In this exploratory and hypothesis-generating study, we sought to elicit the views of patients and caregivers on the merits of various traditional and nontraditional elements of value, as well as other domains that remain uncaptured. Using a modified Delphi approach, we aimed to solicit patient and caregiver feedback on the relative importance of traditional and nontraditional domains of value, and to determine if these views differed according to key demographic or clinical characteristics.

## Methods

### Overview

We used a modified Delphi technique<sup>9</sup> to determine the relative importance of selected domains of value, how patients and caregivers would rank these domains, and whether attitudes might shift once we presented earlier-round results. We identified traditional and nontraditional domains of value based on those described by the “value flower” introduced by ISPOR’s Special Task Force on US Value Assessment Frameworks.<sup>8</sup> We aimed to make all definitions patient-centric, given that the perspective we were most interested in was of the impact of these domains on the daily and individual burden of managing disease (or caring for someone with such a burden). Descriptions of each domain can be found in [Table 1](#). Traditional value domains include: survival, health-related quality of life, productivity, and costs. Nontraditional value domains are comprised of: adherence-improving factors, reductions in uncertainty, fear of contagion, insurance value, severity of disease, value of hope, real option value, equity, and scientific spillovers. Our modified Delphi approach consisted of two electronically conducted survey rounds ([Appendix Exhibit 1](#) and [2](#)), spaced by 3 months, and a 3-week window to complete each round. The first survey round was distributed in mid-August 2021. The Tufts University Health Sciences Institutional Review Board approved survey materials, informed consent, invitation e-mails,

**Table 1** Plain Language Definitions and Illustrative Examples of Each Domain of Value

Domain of Value	Definition
Survival	How long you are expected to live with the condition you have. For example, An effective cancer drug might extend your life by months or years.
Health-related quality of life	The impact of disease on your physical and/or mental health as well as your ability to do your normal activities. For example, If your condition causes fatigue, treatment may improve your energy and ability to conduct your daily activities.
Productivity	The impact of disease on your ability to return to work or school and/or increase how productive you are at work or school. For example, An effective migraine treatment reduces the number of days that you miss work or school and improves your ability to concentrate while at work or school.
Costs	The financial effect on you from the disease and treatment, in terms of both additional amounts you must spend (for example, copayments) and amounts you might save (for example, fewer doctor visits).
Adherence-improving factors	Easier dosing, taking a pill instead of an injection, or other factors that might affect your ability to stick with a health treatment. For example, a multi-pill drug combination becomes available in a single pill.
Reductions in uncertainty	Results from a test that can help guide what treatment you should get and/or help you and your family plan for the future (the “value of knowing”). For example, a test that helps determine whether you are at high risk of developing Alzheimer’s.

(Continued)

**Table 1** (Continued).

Domain of Value	Definition
Fear of contagion	Worry about the spread of an infectious disease and the impact on you and your family. For example, A vaccine can help protect you and others in your community from getting a serious illness.
Insurance value	The benefit of having an effective treatment available for a disease even if you do not currently have the disease. Having good insurance also protects your savings from expensive treatment.
Severity of disease	How much a disease impacts your life and the lives of those around you. For example, Treatments that save the lives of terminally ill people may be valued more than those that eliminate toenail fungus.
Value of hope	The opportunity to take a risky treatment in order to have a small chance of a cure or other substantial benefit. For example, a new cancer treatment has a risk of major side effects but also cures the cancer in a small number of people.
Real option value	The opportunity to receive a treatment that allows you to live long enough to receive the benefits of future advances in medicine. For example, Current treatments for people with HIV allow them to live long enough to receive a cure or an even more effective treatment when it becomes available.
Equity	People with social and/or economic disadvantages are often the ones who suffer the most from a disease. For example, Making sure that essential health workers and other vulnerable groups are at the head of the line for a COVID-19 vaccine.
Scientific spillovers	The benefits of a treatment in terms of the future discoveries that it “unlocks”. For example, the Human Genome Project allowed for the creation of genetic testing that can be used to guide treatment.

and other supporting materials (STUDY00000799). In addition, an individual with chronic illness who also serves in several patient advocacy roles reviewed all survey materials for content and readability.

## Participants

While the existing literature on Delphi methods presents a wide range of commonly used sample sizes appropriate for conducting a Delphi study, the upper range of participants generally lies between approximately 60 and 100.<sup>10,11</sup> Given this range, the nature of the questions posed, and our population of interest, we aimed to recruit 75 participants, consisting of 50 patients and 25 caregivers. Participants were adults over the age of 18 who were managing a chronic medical condition or were a caregiver of a patient with a chronic medical condition. We employed a purposive, non-probability sampling approach with an aim toward recruiting a demographically diverse set of participants who also varied in terms of disease experience. We conducted initial recruitment outreach through the e-mail distribution list of an organization that has been active in discussions about value assessment (Patients Rising Now: <https://patientsrisingnow.org/>); for brevity, we refer to this source as a “patient activist network”. We conducted subsequent recruitment efforts through a notice in The Aging Experience newsletter (<https://www.theagingexperience.com/>), a weekly newsletter distributed to a diverse set of patient and caregiver subscribers that includes news and observations about aging and managing chronic disease; for brevity, we refer to this source as a “general disease advocate network”. All participants received a \$50 Visa gift card only upon completion of both survey rounds.

## Delphi Round 1

Round 1 utilized a structured questionnaire comprised questions about demographic information, such as age and gender, patient or caregiver status, and characterization of chronic medical conditions. Following the demographic questions, the survey asked participants to rate the thirteen domains of value on a 5-point Likert scale (0=“Not Important”, 5=“Very Important”). The survey also prompted participants to rank, in the order of most to least important, domains of value that they had previously rated as “important” or “very important”. To aid in participant understanding of the domains, the rating and ranking sections provided plain language definitions and illustrative examples for each.

At the end of the three weeks, we analyzed responses to survey round 1, excluding incomplete responses. For the rating questions, we flagged domains rated as “important” or “very important” by 55% or more of participants for retention in survey round 2. This cutoff point was determined so that retention was not based on a simple majority of favorable ratings: rather, domains would need to achieve a slightly higher standard of being rated favorably by well over

half of participants. For domains of value that were flagged, we asked participants to rate and rank the domains a second time to evaluate response consistency.

We sent participants a report between survey rounds to remind them how they responded to the first round survey. We also described how a participant's individual responses compared with responses from other participants, giving survey respondents an opportunity to reconsider their responses before completing the second survey round. Finally, we used the first round survey results to inform the development of new questions for the second survey round.

## Delphi Round 2

For the second survey round, we asked participants to review and reconsider their own responses and the aggregated results from survey round 1. The second round asked the same questions as in round 1, with another round of rating and ranking the domains of value. Based on analyses of the round 1 results, we added new questions on whether to retain domains of value that did not achieve the 55% benchmark and questions about challenges patients face in taking medication, including access, out-of-pocket costs, insurance requirements, side effects, and adherence. Furthermore, we added a free-text question to gather information on additional domains of value that participants considered important to their circumstance.

## Statistical Analysis

We computed the average Likert scale response for each domain of value. We used a paired *t*-test to determine if scores for each domain of value changed between the first and second survey rounds. We also used paired *t*-tests to determine if ratings differed across subgroups of interest (for example, patient vs caregiver, recruitment source, age, and gender).

To evaluate the ranked domains of value, we calculated a weighted average score for each. For each participant's ranking, we assigned a weight of 13 to the highest ranked (most important) domain of value, a weight of 12 for next highest ranked, and so on. As above, we used a paired *t*-test to determine if the score for each domain of value differed between the two survey rounds.

Finally, we used multiple logistic regression analysis to identify factors associated with a respondent's designation of a value domain as either "important" or "very important". Covariates included participant type, recruitment source, age, gender, and survey round.

We designated results statistically significant if  $p < 0.05$ ; we also reported confidence intervals for regression-based odds ratios. We conducted our analyses using Stata/SE, version 15.1.


## Results

Our initial recruitment identified 79 individuals who agreed to participate. Figure 1 shows the flow of participants through the two survey stages. Of the 79 participants, 63 (79.7%) completed the first survey round and were eligible to participate in the second round. Ultimately, 58 patients and caregivers completed both rounds. Participants were more likely to be female (60.3%) and between 35 and 54 years of age (58.6%) (Table 2). About two-thirds of participants identified as patients, and we recruited most from the general disease advocate network (70.7%), rather than from the patient activist network (29.3%). Participants recruited via the patient activist network were more likely to be patients (82.4%) than caregivers, while there was a less drastic split between patients (61.0%) and caregivers (39.0%) recruited from the disease advocacy groups. Two-thirds of participants reported having or providing care for one chronic medical condition, while the remainder reported 2 or more chronic medical conditions.

At the end of survey round 1, responses for all domains of value approached our benchmark threshold, with the exception of adherence-improving factors and fear of contagion. The second survey round asked participants if they wanted to retain or "rescue" these two domains.

## Survey Round 1

Using responses from all 63 participants in survey round 1, the domains of scientific spillovers, equity, and costs were rated highest, while value of hope, productivity, fear of contagion, and adherence improving factors were rated lowest. Patients rated the value of hope domain higher than caregivers (3.80 vs 3.14,  $p = 0.01$ ). In comparisons of recruitment



**Figure 1** Flow of participants through the survey rounds.

source, patient activists rated health-related quality of life (4.84 vs 3.25,  $p < 0.001$ ), severity of disease (4.53 vs 3.25,  $p < 0.001$ ), scientific spillovers (4.53 vs 3.59,  $p < 0.001$ ), real option value (4.42 vs 3.34,  $p < 0.001$ ), equity (4.37 vs 3.59,  $p = 0.01$ ), survival (4.32 vs 3.50,  $p < 0.001$ ), reductions in uncertainty (4.21 vs 3.30,  $p < 0.001$ ), value of hope (4.05 vs 3.36,  $p = 0.01$ ), and fear of contagion (3.84 vs 3.20,  $p = 0.03$ ) significantly higher compared to general disease advocates.

**Table 2** Demographic Characteristics of Sample

Variable	Frequency (n=58)	Percent
Sex		
Female	35	60.3%
Age		
18–34	12	20.7%
35–54	34	58.6%
55–64	9	15.5%
65+	3	5.2%

(Continued)

**Table 2** (Continued).

Variable	Frequency (n=58)	Percent
Type of Participant		
Patient	39	67.2%
Caregiver	19	32.8%
Recruitment Source		
Patient Activist Network	17	29.3%
General Disease Advocacy	41	
Number of Conditions		
1	38	65.5%
2+	20	

Although survival and health-related quality of life were not among the highest rated domains individually, participants ranked these traditional domains highest when choosing between them. Additionally, cost was both rated and ranked third highest across all participants. While nontraditional value domains, such as scientific spillovers and equity, were rated highly, and patient activists were more likely to prioritize such measures compared to general disease advocates, they remained ranked below the traditional measures described above.

## Survey Round 2


Approximately 60% of participants indicated a preference for “rescuing” fear of contagion and adherence improving factors, the two domains that were candidates for elimination in round 1. These preferences appeared to be driven by the beliefs of general disease advocates, who were more likely to rate these domains important than patient activists. When asked about financial barriers faced in taking medication, respondents reported out-of-pocket costs to be the biggest challenge (60.3%), while many respondents also rated both insurance requirements (53.4%) and side effects (46.6%) as important.

In response to our open-ended question about other value domains, several respondents added “quality of life” (but without any accompanying text distinguishing this from the quality of life domain already included), and one added “racial and social determinants”. Another respondent wrote that “treatment modalities that lower the patient burden, ie, remote diagnostics, telemedicine, Bluetooth connected devices, etc”. Constituted a separate and important value domain. Finally, one respondent wrote about the importance of mode of administration, describing the importance of the “variety of drug dispensaries such as liquid, pill or patch form”.


## Survey Round Comparison – Ratings and Rankings

Participants could assign different ratings in the two survey rounds for any of the value domains. When comparing responses among the 58 participants who completed both survey rounds, 48% changed their rating for between 2 and 6 domains; 40% changed ratings for between 7 and 9 domains; and 9% assigned different ratings for 10 or more domains. The most frequently changed domains were reduction in uncertainty and value of hope, where 40 participants changed their rating, primarily in a negative direction. The least frequently changed ratings were for health-related quality of life and for severity of disease.

Despite the changes described above, overall ratings and rankings were consistent between survey rounds. Average ratings for each domain of value across both survey rounds are presented in [Figure 2](#). These averages did not differ statistically between rounds for any domain. Similarly, no rankings statistically differed between survey rounds



**Figure 2** Survey round 1 vs survey round 2 average rating for each domain of value in terms of importance (n=58).



**Figure 3** Survey round 1 vs survey round 2 comparison of weighted average of ranked domains of value (n=58).

(Figure 3). Respondents ranked most highly those domains generally considered traditional measures of value, including survival, health-related quality of life, costs, and productivity.

## Factors Associated with Importance Rating

When results from both survey rounds were combined, participants recruited from the patient activist network were approximately six times more likely than general disease advocates to rate each domain of value as important or very important (Odds ratio [OR] 5.68; 95% CI 3.99, 8.07) (Table 3). Other significant factors included age, in which those aged 55–64 were nearly twice as likely as 18–34 year-olds to rate a domain as important or very important (OR 2.10; 95% CI 1.31, 3.37), and those aged 35–54 were 40% more likely to do so (OR 1.40; 95% CI 1.04, 1.89). In contrast, males were less likely to rate any domain of value as important or very important (OR 0.76; 95% CI 0.59, 0.995). Patients were also less likely than caregivers to designate any domain as important or very important (OR 0.57; 95% CI 0.43, 0.76). Findings were similar when examined separately for survey rounds 1 and 2.



**Table 3** Likelihood of Rating Any Domain\* (Important or Very Important) in Rounds 1 and 2

Variable	Odds Ratio	95% Confidence Interval	p-value
Age			
18–34	Ref		
35–54	<b>1.40</b>	(1.04, 1.89)	<b>0.027</b>
55–64	<b>2.10</b>	(1.31, 3.37)	<b>0.002</b>
65+	1.15	(0.59, 2.24)	0.68
Sex			
Female	Ref		
Male	<b>0.76</b>	(0.59, 0.995)	<b>0.046</b>
Type of Participant			
Patient	<b>0.57</b>	(0.43, 0.76)	<b>&lt;0.001</b>
Caregiver	Ref		
Recruitment Source			
Patient Activist Network	<b>5.68</b>	(3.99, 8.07)	<b>&lt;0.001</b>
General Disease Advocacy	Ref		
Survey Round			
Round 1	Ref		
Round 2	1.27	(1.00, 1.62)	0.05

**Notes:** \*Excludes adherence improving factors and fear of contagion from round 1 and round 2. Bold values indicate statistically significant.

## Discussion

Despite our provision of definitions and examples for all domains of value and participation in two survey rounds, participants consistently rated traditional domains of value (survival, quality of life, productivity, and costs) more highly than they rated nontraditional domains (for example, real option value, value of hope). This may be because patients and caregivers can draw on experience with traditional domains of costs, survival, productivity, and quality of life in their daily lives, but domains like value of hope or real option value are more abstract. This finding is supported by a study by Shafrin et al of advanced stage melanoma and lung cancer, which showed that patients placed more value on therapies that might confer a durable survival gain than other alternatives.<sup>12</sup> However, our findings contrast with those from an earlier report, which suggests that patients rate value of hope more highly than traditional outcomes, like expected survival. Lakdawalla et al found that most advanced cancer patients preferred a “hopeful gamble” to a “sure bet” therapy.<sup>13</sup> The difference between our findings and those from Lakdawalla et al largely reflect differences in survey format and the sample frame, with our survey including patients and caregivers experiencing a range of chronic conditions. The survey developed by Lakdawalla et al drew on real-world examples and tradeoffs of cancer treatments, and presented participants with key features of the survival profile of therapies, such as average survival and likelihood of dying within specific timeframes. In contrast to our study and the Shafrin et al study, Lakdawalla et al also asked participants to consider their willingness to pay for therapies with differing outcomes.

The most important factor associated with respondent importance ratings was recruitment source. Respondents we recruited from the patient activist network placed more importance on all value domains than respondents recruited from the general disease advocacy group. Patient activists may believe that value frameworks limit a patient’s access to therapies and focus too much on costs.<sup>6</sup> These beliefs might increase the probability that they will rank many domains of



value as important. These types of differences in context and perspective are critical to the research and policy community as possible changes to standard measures of health gain are considered.

This study has a number of limitations. First, the survey's aim was exploratory and hypothesis-generating, with limitations on the sample size and survey scope. Second, there are known limitations to the generalizability of Delphi results due to the sample size and the potential uneven distribution of preexisting opinions;<sup>14</sup> in our case, exploration of differences across multiple matrices (eg, recruitment source and patient/caregiver status) was not possible. Third, as an exploratory exercise, the results do not establish consensus; rather, they provide important information for future research in this area. Fourth, there may have been limitations that arose from providing summary round 1 results to all participants before the administration of survey round 2 that could have skewed the results in either direction or towards the sample mean. We note, however, that despite changes in individual ratings and rankings, these measures were quite consistent between rounds on an overall basis. Finally, we could not account for the level of previous knowledge each respondent may have had with regard to the nontraditional value domains. We aimed to address potential differences in background knowledge by defining the value domains and providing illustrative examples for each.

Nonetheless, we believe that this study represents the first attempt to seek patient and caregiver opinions regarding the importance of both traditional and nontraditional domains of value. Our findings indicate that patients and caregivers put significant stock in traditional and well-accepted measures of the value of health innovations, suggesting that further research into nontraditional value domains should focus on augmenting and bolstering traditional measures. In addition, our results indicate that the recruitment source of patients and caregivers may significantly impact what they consider to be important in value assessment. Further research in this area might integrate consideration of individual tradeoffs between value domains, as well as the implications of expanded value assessments in the context of fixed or constrained health system budgets.

## Ethics Approval and Informed Consent

The Tufts University Health Sciences Institutional Review Board approved survey materials, informed consent, invitation e-mails, and other supporting materials. The present study was conducted in compliance with the ethical principles for research documented in the Declaration of Helsinki.

## Acknowledgments

The authors would like to thank Joshua T. Cohen, PhD for his contributions toward the editing of the manuscript. This work was supported by the PhRMA Foundation Center for Excellence in Value Assessment Award.

## Disclosure

Mr. Voehler, Dr. Neumann, and Dr. Ollendorf are employed by the Tufts Center for the Evaluation of Value and Risk in Health, which maintains a variety of databases that are sponsored by life sciences companies, government agencies, and academic institutions. However, neither our principal funder nor any of our center's sponsors had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. In addition, Dr. Neumann also reports grants from NPC, NIH, Alzheimer's Association, Arnold Ventures, BMS, Otsuka, and Traveco; funding to The CEA registry from NSF, NLM, AHRQ, CDC, and a variety of [pharmaceutical and device companies and non-profits](https://cevr.tuftsmedicalcenter.org/sponsorship) which subscribe to the data (<https://cevr.tuftsmedicalcenter.org/sponsorship>); personal fees from CBO, Bayer, Panalgo, Merck, ArgenX, and Novartis Gene Therapy Sarepta (consulting), outside the submitted work. Dr. Ollendorf reports grants from PhRMA Foundation, during the conduct of the study; grants from Merck Sharp & Dohme and Commonwealth Fund; personal fees from GlaxoSmithKline and University of Colorado, outside the submitted work. The authors report no other conflicts of interest in this work.

## References

1. Center for the Evaluation of Value and Risk in Health. The cost-effectiveness analysis registry. Boston: Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. Available from: [www.cearegistry.org](http://www.cearegistry.org). Accessed February 17, 2012.
2. Neumann PJ. Why don't Americans use cost-effectiveness analysis? *Am J Manag Care*. 2004;10(5):308–312.

3. Chambers JD, Chenoweth MD, Neumann PJ. Mapping US commercial payers' coverage policies for medical interventions. *Am J Manag Care*. 2016;22(9):e323–e328.
4. Peretto EM. ISPOR's initiative on US value assessment frameworks: a missed opportunity for ISPOR and patients. *Value Health*. 2018;21(2):169–170. doi:10.1016/j.jval.2017.12.002
5. Neumann PJ, Cohen JT. QALYs in 2018—advantages and concerns. *JAMA*. 2018;319(24):2473–2474. doi:10.1001/jama.2018.6072
6. John. ICER watch: why patients must fight ICER's plan to cap treatments; 2016. Available from: <https://www.patientsrising.org/icer-plan-to-cap-treatments/>. Accessed December 8, 2022.
7. Thorpe KE. Don't legalize discrimination against people with disabilities; 2020. Available from: <https://www.tennessean.com/story/opinion/2020/01/14/dont-legalize-discrimination-against-people-disabilities-qaly-quality-adjusted-life-year/4468426002/?fbclid=IwAR3mgjY9GoOQ2PPQ9kedn3yCEeSgasRmuMsg63aoWSLw2GPafyNFOzAjkck>. Accessed December 8, 2022.
8. Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care—a health economics approach: an ISPOR special task force report [3]. *Value Health*. 2018;21(2):131–139. doi:10.1016/j.jval.2017.12.007
9. Dalkey NC. *The Delphi Method: An Experimental Study of Group Opinion*. Santa Monica, CA: RAND Corporation; 1969.
10. Grisham T. The Delphi technique: a method for testing complex and multifaceted topics. *Int J Manag Project Bus*. 2009;2(1):112–130. doi:10.1108/17538370910930545
11. Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. *Int J Forecast*. 1999;15(4):353–375. doi:10.1016/S0169-2070(99)00018-7
12. Shafrin J, Schwartz TT, Okoro T, Romley JA. Patient versus physician valuation of durable survival gains: implications for value framework assessments. *Value Health*. 2017;20(2):217–223. doi:10.1016/j.jval.2016.11.028
13. Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. *Health Aff*. 2012;31(4):676–682. doi:10.1377/hlthaff.2011.1300
14. Fink-Hafner D, Dagen T, Doušak M, Novak M, Hafner-Fink M. Delphi method: strengths and weaknesses. *Adv Methodol Stat*. 2019;2:1–19.

## Patient Preference and Adherence

Dovepress

### Publish your work in this journal

Patient Preference and Adherence is an international, peer-reviewed, open access journal that focusing on the growing importance of patient preference and adherence throughout the therapeutic continuum. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease states are major areas of interest for the journal. This journal has been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/patient-preference-and-adherence-journal>